Brown Advisory Inc Nymox Pharmaceutical Corp Transaction History

Brown Advisory Inc

6 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2022 Nov 14, 2022	BUY	$0.22 - $0.61 $6,160 - $17,080	28,000 New	28,000 $12,000
Q4 2021 Jan 27, 2022	SELL	$0.95 - $2.1 $17,765 - $39,270	-18,700 Closed	0 $0
Q1 2020 May 15, 2020	SELL	$1.69 - $3.88 $13,520 - $31,040	-8,000 Reduced 29.96%	18,700 $44,000
Q4 2018 Feb 13, 2019	BUY	$1.31 - $2.53 $34,977 - $67,551	26,700 New	26,700 $34,000
Q3 2018 Nov 13, 2018	SELL	$2.46 - $3.7 $65,682 - $98,790	-26,700 Closed	0 $0
Q1 2018 May 14, 2018	BUY	$3.09 - $4.43 $82,503 - $118,280	26,700 New	26,700 $113,000

150K

Ticker NYMX
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 91,265,000
Market Cap $42.9M
Description
Nymox Pharmaceutical Corporation, a biopharmaceutical company, engages in the research and development of drugs for the aging population in Canada, the United States, Europe, and internationally. Its lead drug candidate is Fexapotide Triflutate (NX-1207), which has completed Phase III clinical trials for the treatment of benign prostatic hyperpl...

Get notified when there are updates to the investment portfolio of Brown Advisory Inc, based on Form 13F filings with the SEC.

Stay updated on Brown Advisory Inc with notifications on news.